On Thursday, CME Group Cl A reached an important technical milestone, with its Relative Strength (RS) Rating jumping into the 80-plus percentile with an improvement to 81, a rise from 77 the day before.
IBD's proprietary RS Rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up against that of other stocks on the major indexes.
Over 100 years of market history shows that the top-performing stocks typically have an RS Rating of at least 80 as they launch their biggest price moves.
Looking For The Best Stocks To Buy And Watch? Start Here
CME Group Cl A is within a buy range after breaking past a 249.02 entry in a cup without handle. Once a stock moves 5% or higher beyond the original entry, it's considered out of buy range.
The company posted 6% EPS growth in the latest quarterly report. Revenue increased 6%.
The company earns the No. 16 rank among its peers in the Financial Services-Specialty industry group. Marex Group, Sezzle and Qifu Technology ADR are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
